Recently carbon spinal implants have been introduced in the treatment of patients with metastatic spinal cord compression (MSCC). This is expected to decrease the deflection of radiation and improve diagnostic imaging and radiotherapy when compared to titanium implants. The aim of this study was to determine the safety and effectiveness of spinal carbon instrumentation (CI) in patients with MSCC in a large cohort study. A total of 163 patients received instrumentation between 1 January 2017 and 31 December 2021. A total of 80 were stabilized with CI and 83 with TI. The outcome measures were surgical revision, postsurgical survival, peri-operative bleeding, and surgery time. The peri-operative blood loss in the CI-group was significantly lower than that in the TI-group: 450mL vs. 630mL, (p= 0.02). There were no significant differences between the groups in mean survival (CI 9.9) vs. (TI 12.9) months (p= 0.39), or the number of patients needing a revision (CI 6) vs. (TI 10), (p= 0.39). The median duration of surgery was 121 min, (p= 0.99) with no significant difference between the two groups. Surgical treatment with CI for MSCC is safe and an equally sufficient treatment when compared to TI.
近年来，碳质脊柱植入物已被引入用于治疗转移性脊髓压迫症（MSCC）患者。与钛质植入物相比，预计能减少辐射偏转，并改善诊断成像和放射治疗的效果。本研究旨在通过一项大规模队列研究，确定脊柱碳质器械（CI）在MSCC患者中的安全性和有效性。在2017年1月1日至2021年12月31日期间，共有163名患者接受了器械植入手术，其中80名患者使用CI进行稳定，83名患者使用TI进行稳定。研究结果指标包括手术翻修率、术后生存期、围手术期出血量和手术时间。CI组的围手术期失血量显著低于TI组：450毫升对630毫升（p=0.02）。两组在平均生存期（CI组9.9个月对TI组12.9个月，p=0.39）或需要翻修的患者数量（CI组6人对TI组10人，p=0.39）方面均无显著差异。手术中位时长为121分钟（p=0.99），两组之间无显著差异。与TI相比，使用CI进行MSCC手术治疗是安全的，且治疗效果相当充分。
Carbon Instrumentation in Patients with Metastatic Spinal Cord Compression
肿瘤(癌症)患者之家